OCT 0 4 2005

02:54:18 p.m. 10-04-2005 1/14

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re United States Patent Application of:

Docket No.:

4080-130

Applicant:

CHANG, Kwen-Jen, et al.

Examiner:

Unassigned

Application No.:

10/749,437

Art Unit:

1614

Date Filed:

December 31, 2003

Conf. No.:

8959

Title:

CARDIOPROTECTIVE

DELTA OPIOID RECEPTOR

AGONISTS AND METHODS

OF USING SAME

Customer No.:

23448

FACSIMILE TRANSMISSION CERTIFICATE Fax No. (571) 273-8300

I hereby certify that this document is being filed in the United States Patent and Trademark Office, via facsimile transmission to Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on October 4, 2005, to United States Patent and Trademark Office facsimile transmission number (571) 273-8300.

Number of Pages (including cover)

Joahna Joslyn

October 4, 2005

Date

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO/SB/08A. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

⊠ 1.	This In OR be require	formation Disclosure Statement is being filed within three months of the U.S. filing date fore the mailing date of a first Office Action on the merits. No certification or fee is d.		
2 .	This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.			
	☐ a.	I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).		
	□ Ь.	I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).		
	☐ c.	Attached is our check no in the amount of \$ in payment of the fee under 37 C.F.R. §1.17(p). Please credit or debit Deposit Account No as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.		
date and after the mailing date of a Final Rejection or Not of the Issue Fee. Applicant(s) hereby petition(s) that the considered. Attached is our check no in the amoun fee under 37 C.F.R. §1.17(p). Please credit or debit Dep		formation Disclosure Statement is being filed more than three months after the U.S. filing d after the mailing date of a Final Rejection or Notice of Allowance, but before payment Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be cred. Attached is our check no in the amount of \$180.00 in payment of the petition ler 37 C.F.R. §1.17(p). Please credit or debit Deposit Account No as needed to consideration of the disclosed information. Two duplicate copies of this paper are d.		
	☐ a.	I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).		
	□ в.	I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement 37 CFR 81.97(e)(2)		

10-04-2005

Respectfully submitted,

Marianne Fuierer Reg. No. 39,983

Attorney for Applicants

INTELLECTUAL PROPERTY/ TECHNOLOGY LAW Telephone: (919) 419-9350 Fax: (919) 419-9354 Attorney Ref: 4080-130

RECEIVED CENTRAL FAX CENTER

02:55:07 p.m. 10-04-2005

4/14

OCT 0 4 2005

PTC/SB/08A (01-04) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

COMPLETE IF KNOWN Application Number 10/749,437 SUPPLEMENTAL Filing Date **INFORMATION** December 31, 2003 **DISCLOSURE STATEMENT** First Named Inventor CHANG, Kwen-Jen, et al. BY APPLICANT Art Unit 1614 Examiner Name Unassigned Sheet 1 of 3 Attorney Docket Number 4080-130

		U.S. P.	ATENT DOCUMENT	S	
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	AI	US-6,200,978		03/13/2001	Maw, et al.
	AJ	US-20020052007	05-02-2002		Chang, et al.
		US-			
	ľ	US-			
		US-			

Examiner	Date
signature	1
Digitator	Considered

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

¹ All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).

RECEIVED CENTRAL FAX CENTER

02:55:25 p.m.

10-04-2005

5/14

OCT 0 4 2005

COMPLETE IF KNOWN Application Number 10/749,437 **SUPPLEMENTAL** Filing Date **INFORMATION** December 31, 2003 **DISCLOSURE STATEMENT** First Named Inventor CHANG, Kwen-Jen, et al. BY APPLICANT Art Unit 1614 Examiner Name Unassigned Sheet 2 of 3 Attorney Docket Number 4080-130

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation	
	AK	WO 99/01438 A1	01-14-1999	Astra Aktiebolag	YES	NO ¹
	AIX	#0 93/01436 AT	01-14-1999	Asua Aktiebolag	-	
		,				
						<u> </u>
						
			-		-	\vdash
						-
						ļ
		<u> </u>	-			
·····			-		ļ	
			 		ļ	
					·	
						
		1.				1

Examiner	Date	
signature	Considered	ļ ·

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).

SUPPLEMENTAL
INFORMATION
DISCLOSURE STATEMENT
BY APPLICANT

Sheet 3 of 3

Application Number 10/749,437

Filing Date December 31, 2003

First Named Inventor CHANG, Kwen-Jen, et al.

Art Unit 1614

Examiner Name Unassigned

Attorney Docket Number 4080-130

Examiner Initials*

| Cite Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published

| AL | ITO et al., "U-92032, a T-type Ca²⁺ channel blocker and antioxidant, reduces neuronal ischemic injuries", European Journak of Pharmacology, (1994), 257, 203-325.

Examiner	Date
signature	Considered

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

² Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).